These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 17002161)

  • 21. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP
    J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of statins in managing diabetic dyslipidemia.
    Toth PP
    J Fam Pract; 2010 May; 59(5 Suppl):S23-9. PubMed ID: 20544054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
    Taskinen MR
    Nutr Metab Cardiovasc Dis; 2006 Dec; 16(8):509-12. PubMed ID: 17071064
    [No Abstract]   [Full Text] [Related]  

  • 24. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD; Banga JD; Erkelens DW
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
    Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2008 Jun; 101(11):1679-80. PubMed ID: 18489951
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
    Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Statin treatment in type 2 diabetes. Is it a must today?].
    Faust M
    MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Good prevention of type 2 diabetes with lipid-lowering statin therapy. Intervention studies support active treatment of risk patients].
    Nilsson PM; Attvall S; Båvenholm P
    Lakartidningen; 2004 Nov; 101(47):3798, 3801-2, 3804. PubMed ID: 15609534
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of treat-to-target strategy for LDL-cholesterol control in type 2 diabetes: post-hoc analysis of data from the MIND.IT study.
    Ardigò D; Vaccaro O; Cavalot F; Rivellese AA; Franzini L; Miccoli R; Patti L; Boemi M; Trovati M; Zavaroni I;
    Eur J Prev Cardiol; 2014 Apr; 21(4):456-63. PubMed ID: 23147277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 40. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.